CD44 Antibody (C-term) [Knockout Validated]
Purified Rabbit Polyclonal Antibody (Pab) KO
- SPECIFICATION
- CITATIONS: 5
- PROTOCOLS
- BACKGROUND
Application
| WB |
---|---|
Primary Accession | P16070 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 81538 Da |
Isotype | Rabbit IgG |
Antigen Source | HUMAN |
Gene ID | 960 |
---|---|
Other Names | CD44 antigen, CDw44, Epican, Extracellular matrix receptor III, ECMR-III, GP90 lymphocyte homing/adhesion receptor, HUTCH-I, Heparan sulfate proteoglycan, Hermes antigen, Hyaluronate receptor, Phagocytic glycoprotein 1, PGP-1, Phagocytic glycoprotein I, PGP-I, CD44, CD44, LHR, MDU2, MDU3, MIC4, knockout |
Dilution | WB~~1:2000 |
Target/Specificity | This CD44 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 688-722 amino acids from the C-terminal region of human CD44. |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | CD44 Antibody (C-term) [Knockout Validated] is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CD44 |
---|---|
Synonyms | LHR, MDU2, MDU3, MIC4 |
Function | Cell-surface receptor that plays a role in cell-cell interactions, cell adhesion and migration, helping them to sense and respond to changes in the tissue microenvironment (PubMed:16541107, PubMed:19703720, PubMed:22726066). Participates thereby in a wide variety of cellular functions including the activation, recirculation and homing of T-lymphocytes, hematopoiesis, inflammation and response to bacterial infection (PubMed:7528188). Engages, through its ectodomain, extracellular matrix components such as hyaluronan/HA, collagen, growth factors, cytokines or proteases and serves as a platform for signal transduction by assembling, via its cytoplasmic domain, protein complexes containing receptor kinases and membrane proteases (PubMed:18757307, PubMed:23589287). Such effectors include PKN2, the RhoGTPases RAC1 and RHOA, Rho-kinases and phospholipase C that coordinate signaling pathways promoting calcium mobilization and actin-mediated cytoskeleton reorganization essential for cell migration and adhesion (PubMed:15123640). |
Cellular Location | Cell membrane; Single-pass type I membrane protein. Cell projection, microvillus {ECO:0000250|UniProtKB:P15379}. Secreted Note=Colocalizes with actin in membrane protrusions at wounding edges Co-localizes with RDX, EZR and MSN in microvilli. Localizes to cholesterol-rich membrane-bound lipid raft domains {ECO:0000250|UniProtKB:P15379, ECO:0000269|PubMed:23589287} |
Tissue Location | Detected in fibroblasts and urine (at protein level) (PubMed:25326458, PubMed:36213313, PubMed:37453717). Detected in placenta (at protein level) (PubMed:32337544). Isoform 10 (epithelial isoform) is expressed by cells of epithelium and highly expressed by carcinomas. Expression is repressed in neuroblastoma cells |
Provided below are standard protocols that you may find useful for product applications.
Background
Receptor for hyaluronic acid (HA). Mediates cell-cell and cell-matrix interactions through its affinity for HA, and possibly also through its affinity for other ligands such as osteopontin, collagens, and matrix metalloproteinases (MMPs). Adhesion with HA plays an important role in cell migration, tumor growth and progression. In cancer cells, may play an important role in invadopodia formation. Also involved in lymphocyte activation, recirculation and homing, and in hematopoiesis. Altered expression or dysfunction causes numerous pathogenic phenotypes. Great protein heterogeneity due to numerous alternative splicing and post-translational modification events.
References
Stamenkovic I.,et al.Cell 56:1057-1062(1989).
Harn H.-J.,et al.Biochem. Biophys. Res. Commun. 178:1127-1134(1991).
Stamenkovic I.,et al.EMBO J. 10:343-348(1991).
Dougherty G.J.,et al.J. Exp. Med. 174:1-5(1991).
Kugelman L.C.,et al.J. Invest. Dermatol. 99:886-891(1992).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.